We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

160 hedge funds and large institutions have $2.47B invested in Pacira BioSciences in 2014 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 57 increasing their positions, 47 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

290% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 10

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

72% more call options, than puts

Call options by funds: $11.1M | Put options by funds: $6.45M

22% more capital invested

Capital invested by funds: $2.02B → $2.47B (+$448M)

21% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 47

21% more funds holding

Funds holding: 132 → 160 (+28)

Holders
160
Holders Change
+28
Holders Change %
+21.21%
% of All Funds
4.62%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.2%
New
39
Increased
57
Reduced
47
Closed
10
Calls
$11.1M
Puts
$6.45M
Net Calls
+$4.67M
Net Calls Change
-$1.53M

Top Buyers

1
MCM
Marsico Capital Management
Colorado
+$47.2M
2
NCGI
Next Century Growth Investors
Minnesota
+$24.3M
3
O
OppenheimerFunds
New York
+$22M
4
CCI
Columbus Circle Investors
+$21.2M
5
Millennium Management
Millennium Management
New York
+$16.8M

Top Sellers

1
AllianceBernstein
AllianceBernstein
Tennessee
-$39M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$37M
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$32.6M
4
GGHC
Gilder Gagnon Howe & Co
New York
-$30.2M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$27.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
101
Eventide Asset Management
Massachusetts
$931K – – –
Citadel Advisors
102
Citadel Advisors
Florida
$882K +$855K +12,573 +44,904%
GPCM
103
Granite Point Capital Management
Massachusetts
$868K +$843K +12,400 New
SI
104
Standard Investments
New York
$865K +$218K +3,206 +35%
TIM
105
Thornburg Investment Management
New Mexico
$854K -$170K -2,500 -17%
CAM
106
Castlerock Asset Management
New York
$820K +$797K +11,721 New
T
107
TradeWorx
New Jersey
$801K +$778K +11,441 New
U
108
UBS
Switzerland
$761K -$514K -7,556 -41%
FSA
109
Franklin Street Advisors
North Carolina
$749K -$301K -4,425 -29%
PG
110
PEAK6 Group
Illinois
$737K +$716K +10,534 New
Goldman Sachs
111
Goldman Sachs
New York
$735K +$259K +3,812 +57%
TFCP
112
Twin Focus Capital Partners
Massachusetts
$716K +$16.5K +242 +2%
SEC
113
Seven Eight Capital
New York
$707K +$687K +10,100 New
WMSA
114
Weiss Multi-Strategy Advisers
New York
$700K +$680K +10,000 New
ARC
115
Absolute Return Capital
Massachusetts
$694K +$674K +9,912 New
Principal Financial Group
116
Principal Financial Group
Iowa
$609K -$5.64K -83 -0.9%
AI
117
Axiom Investors
Connecticut
$597K +$580K +8,530 New
PP
118
PDT Partners
New York
$553K +$537K +7,900 New
Citigroup
119
Citigroup
New York
$531K -$429K -6,314 -45%
HFS
120
HL Financial Services
Kentucky
$485K -$102K -1,506 -18%
BFG
121
Bouchey Financial Group
New York
$420K – – –
Connor, Clark & Lunn Investment Management (CC&L)
122
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$417K +$367K +5,400 New
HLA
123
Hamilton Lane Advisors
Pennsylvania
$408K +$397K +5,831 New
Jane Street
124
Jane Street
New York
$360K +$350K +5,150 New
NSAM
125
North Star Asset Management
Wisconsin
$350K +$340K +5,000 New
3 4
5
6 7

PCRX Hedge Fund Activity: Q1 2014 in Review

160 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2014, worth a combined $2.47B — up 22% from $2.02B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new PCRX positions and 10 closed out — a net gain of 29 holders — while 57 added to existing stakes and 47 trimmed.

The largest buyer was Marsico Capital Management, adding an estimated $47.2M. The largest seller was AllianceBernstein, cutting an estimated $39M.

  • 160 institutional investors held Pacira BioSciences (PCRX) as of Q1 2014, up from 132 in Q4 2013.
  • Funds reported $2.47B of Pacira BioSciences stock for Q1 2014, up 22% quarter-over-quarter.
  • 39 funds opened new Pacira BioSciences positions in Q1 2014 and 10 closed out, a net change of +29 holders.
  • The largest Pacira BioSciences buyer in Q1 2014 was Marsico Capital Management, an estimated $47.2M added.
  • The largest Pacira BioSciences seller in Q1 2014 was AllianceBernstein, an estimated $39M sold.

Based on aggregated 13F filings for Q1 2014.